Reports
Sale
Global Controlled Release Drug Delivery Market Size, Report: By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Others; By Mechanism: Polymer Based Systems, Others; By Applications; By End User; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Global Controlled Release Drug Delivery Market Outlook
The global controlled release drug delivery market size was valued at USD 54.8 billion in 2023, driven by the emphasis on reducing medication related side-effects across the globe. The market is expected to grow at a CAGR of 10.4% during the forecast period of 2024-2032, with the values likely to rise from USD 60.5 billion in 2024 to USD 134 billion by 2032.
Controlled Release Drug Delivery: Introduction
Controlled release drug delivery is done to achieve the optimal drug-serum concentration by releasing drugs in a rational programed rate. This system can allow reduced drug administration, better drug absorption, and lesser side effects. It can enhance the efficacy, safety, and convenience of drug therapy in patients. Controlled release drug delivery is commonly done via oral and transdermal administration, among others.
Global Controlled Release Drug Delivery Market Analysis
Traditional drug formulations are often associated with unwanted side effects, painful administration, infusion related toxicity, immunocompromised host, and antimicrobial resistance. To address such concerns, researchers have diverted towards new methods of drug administration, leading to accelerated controlled release drug delivery market value.
Recently, electrospun nanofibers have emerged as a new advancement in controlled drug release market strategies. Most of the benefits lie in the cost, easy programmability, versatility, and scalability of the nanofibers. They can be easily customized based on orientation, size, and the nature of polymers.
The controlled release drug delivery market growth is driven by the increasing engagement of impactful healthcare companies to develop better alternative for patients. AstraZeneca has recently come up with several new options to make drug administration convenient. Biodegradable implants are a prime example. PLGA (poly lactic-co-glycolic acid) and polycaprolactone are being used to store medicines and release them as per the diffusion and degradation characteristics of the particles.
Another method is the atomic layer deposition of metal oxides. It is a dry, metal oxide film deposition that allows sustained release for prolonged period, followed by nano shell formation on the surface. The Silica particle-based controlled release is also being investigated and may be a preferred alternative in the future.
Global Controlled Release Drug Delivery Market Segmentation
Market Breakup by Technology
- Wurster Technique
- Coacervation
- Micro Encapsulation
- Implants
- Transdermal
- Targeted Delivery
- Others
Market Breakup by Mechanism
- Polymer Based Systems
- Micro Reservoir Partition Controlled Drug Delivery Systems
- Feedback Regulated Drug Delivery Systems
- Activation-modulated Drug Delivery Systems
- Osmotic Pressure Activated
- Hydrodynamic Pressure Activated
- Vapor Pressure Activated
- Mechanically Activated
- Magnetically Activated
- Chemically Activated
- pH Activated
- Hydrolysis Activated
- Enzyme Activated
Market Breakup by Applications
- Metered Dose Inhalers
- Injectable
- Transdermal and Ocular Patches
- Infusion Pumps
- Oral Controlled-drug Delivery Systems
- Drug Eluting Stents
Market Breakup by End User
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Controlled Release Drug Delivery Market Overview
The controlled release drug delivery market share was dominated by the United States during the historical period. The growing market size can be attributed to a well-developed healthcare infrastructure and a strong focus on research and development. With significant investments in advanced technologies, the regulatory bodies pertaining to the area also play a critical role in maintaining the efficacy of drug administration.
Europe, having prominent research and academic institutions, along with key healthcare companies, is a major player in the market. The market growth is highly driven by the growing partnerships between research institutions and healthcare companies, aimed at offering better drug delivery technologies to the patients.
With rising geriatric population and high incidence of chronic diseases, Asia Pacific countries are experiencing high controlled release drug delivery market demand. Factors like rising infrastructure development, disposable incomes, and growing awareness of advanced treatment options are further fueling the market growth. Private sectors are also playing a huge part in improving the healthcare ecosystem and fostering innovative drug delivery systems.
Global Controlled Release Drug Delivery Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc (GSK)
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Alkermes plc.
- UCB S.A.
- Vectura Group plc.
- Coating Place, Inc.
- Skyepharma Production S.A.
- Capsugel
- Depomed, Inc.
- Aradigm Corporation
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Mechanism |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Controlled Release Drug Delivery Market Overview
3.1 Global Controlled Release Drug Delivery Market Historical Value (2017-2023)
3.2 Global Controlled Release Drug Delivery Market Forecast Value (2024-2032)
4 Global Controlled Release Drug Delivery Market Landscape
4.1 Global Controlled Release Drug Delivery Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Controlled Release Drug Delivery Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Application
5 Global Controlled Release Drug Delivery Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Controlled Release Drug Delivery Market Segmentation
6.1 Global Controlled Release Drug Delivery Market by Technology
6.1.1 Market Overview
6.1.2 Wurster Technique
6.1.3 Coacervation
6.1.4 Micro Encapsulation
6.1.5 Implants
6.1.6 Transdermal
6.1.7 Targeted Delivery
6.1.8 Others
6.2 Global Controlled Release Drug Delivery Market by Mechanism
6.2.1 Market Overview
6.2.2 Polymer Based Systems
6.2.3 Micro Reservoir Partition Controlled Drug Delivery Systems
6.2.4 Feedback Regulated Drug Delivery Systems
6.2.5 Activation-modulated Drug Delivery Systems
6.2.5.1 Osmotic Pressure Activated
6.2.5.2 Hydrodynamic Pressure Activated
6.2.5.3 Vapor Pressure Activated
6.2.5.4 Mechanically Activated
6.2.5.5 Magnetically Activated
6.2.6 Chemically Activated
6.2.6.1 pH Activated
6.2.6.2 Hydrolysis Activated
6.2.6.3 Enzyme Activated
6.3 Global Controlled Release Drug Delivery Market by Applications
6.3.1 Market Overview
6.3.2 Metered Dose Inhalers
6.3.3 Injectable
6.3.4 Transdermal and Ocular Patches
6.3.5 Infusion Pumps
6.3.6 Oral Controlled-drug Delivery Systems
6.3.7 Drug Eluting Stents
6.4 Global Controlled Release Drug Delivery Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Ambulatory Surgical Centers
6.4.4 Cancer Research Institutes
6.4.5 Others
6.5 Global Controlled Release Drug Delivery Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Controlled Release Drug Delivery Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Controlled Release Drug Delivery Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Controlled Release Drug Delivery Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Controlled Release Drug Delivery Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Controlled Release Drug Delivery Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 Johnson & Johnson
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisition
18.1.5 Certifications
18.2 Novartis AG
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisition
18.2.5 Certifications
18.3 Pfizer Inc.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisition
18.3.5 Certifications
18.4 GlaxoSmithKline plc (GSK)
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisition
18.4.5 Certifications
18.5 Merck & Co., Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisition
18.5.5 Certifications
18.6 Bristol Myers Squibb Company
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisition
18.6.5 Certifications
18.7 Eli Lilly and Company
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisition
18.7.5 Certifications
18.8 Alkermes plc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisition
18.8.5 Certifications
18.9 UCB S.A.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisition
18.9.5 Certifications
18.10 Vectura Group plc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisition
18.10.5 Certifications
18.11 Coating Place, Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisition
18.11.5 Certifications
18.12 Skyepharma Production S.A.
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisition
18.12.5 Certifications
18.13 Capsugel
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisition
18.13.5 Certifications
18.14 Depomed, Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisition
18.14.5 Certifications
18.15 Aradigm Corporation
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisition
18.15.5 Certifications
19 Global Controlled Release Drug Delivery Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 54.8 billion in 2023, driven by the focus on reducing medication associated side effects across the globe.
The market is anticipated to grow at a CAGR of 10.4% during the forecast period of 2024-2032, likely to reach a market value of USD 134 billion by 2032.
The market demand is driven by the benefits of controlled release drug delivery systems. It can help in the drug delivery optimisation, along with maintaining therapeutic levels for a prolonged time.
The current market trend revolves around the rising application of biodegradable implants in controlled release drug delivery systems. AstraZeneca has started using PLGA (poly lactic-co-glycolic acid) and polycaprolactone to release particles based on the diffusion time.
Based on technology, the market is divided into Wurster technique, coacervation, micro encapsulation, implants, transdermal, and targeted delivery, among others.
It includes polymer-based systems, micro reservoir partition-controlled drug delivery systems, feedback regulated drug delivery systems, activation-modulated drug delivery systems, and chemically activated.
The drug delivery finds wide applications in metered dose inhalers, injectable, transdermal and ocular patches, infusion pumps, oral controlled-drug delivery systems, and drug eluting stents.
Major end users include hospitals, ambulatory surgical centers, and cancer research institutes, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Alkermes plc., UCB S.A., Vectura Group plc., Coating Place, Inc., Skyepharma Production S.A., Capsugel, Depomed, Inc., and Aradigm Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER